R
Richard Bucala
Researcher at Yale University
Publications - 622
Citations - 58697
Richard Bucala is an academic researcher from Yale University. The author has contributed to research in topics: Macrophage migration inhibitory factor & Cytokine. The author has an hindex of 119, co-authored 595 publications receiving 54607 citations. Previous affiliations of Richard Bucala include École Polytechnique Fédérale de Lausanne & Rockefeller University.
Papers
More filters
Journal ArticleDOI
Editorial: A Fresh New Look, and a Fresh New Journal.
Richard Bucala,Marian T. Hannan +1 more
Journal ArticleDOI
Site-specific modification of apolipoprotein B by advanced glycosylation end-products: implications for lipoprotein clearance and atherogenesis
TL;DR: A low but detectable degree of AGE modification was found to affect this site in LDL which was isolated from normal, non-diabetic individuals, suggesting that advanced glycosylation may contribute to elevated LDL in the general population as well.
Journal ArticleDOI
Balance between macrophage migration inhibitory factor and sCD74 predicts outcome in patients with acute decompensation of cirrhosis
Theresa H. Wirtz,Philipp A. Reuken,Christian Jansen,P Fischer,Irina Bergmann,Christina Backhaus,Christoph Emontzpohl,J Reißing,EF Brandt,M. Teresa Koenen,Kai Markus Schneider,Robert Schierwagen,Maximilian J. Brol,Johannes Chang,Henning W. Zimmermann,Nilay Köse-Vogel,Thomas Eggermann,Ingo Kurth,Christian Stoppe,Richard Bucala,Jürgen Bernhagen,Michael Praktiknjo,Andreas Stallmach,Christian Trautwein,Jonel Trebicka,Tony Bruns,Marie-Luise Berres +26 more
TL;DR: Serum concentrations of MIF and its soluble receptor CD74 predict 90-day transplant-free survival in patients with acute decompensation of cirrhosis and show that patients with high serum levels of the inflammatory cytokine macrophage migration inhibitory factor alongside low levels of its binding receptor sCD74 in blood indicate an increased mortality risk in patientsWith ascites.
Journal ArticleDOI
Role of Macrophage Migration Inhibitory Factor in Granulomatosis With Polyangiitis.
Antoine G. Sreih,Rana Ezzedine,Lin Leng,Juan Fan,Jie Yao,Duncan Reid,Marta Piecychna,Simon Carette,David Cuthbertson,Paul F. Dellaripa,Gary S. Hoffman,Nader Khalidi,Curry L. Koening,Carol A. Langford,Alfred Mahr,Carol A. McAlear,Kathleen Maksimowicz-McKinnon,Paul A. Monach,Philip Seo,Ulrich Specks,E. William St. Clair,John H. Stone,Steven R. Ytterberg,Jeffrey C. Edberg,Peter A. Merkel,Richard Bucala +25 more
TL;DR: To examine the association between macrophage migration inhibitory factor promoter polymorphisms and granulomatosis with polyangiitis (GPA) in human subjects, and to assess the role of MIF in a murine model of granulOMatous vasculitis.
Patent
Diagnostic assays for MIF
TL;DR: The use of migration inhibitory factor (MIF) for the treatment of various conditions involving cytokine-mediated toxicity, which include, but are not limited to, shock, inflammation, graft versus host disease, and/or autoimmune diseases is discussed in this paper.